Lessons From Trasylol Side Effects And Safety Studies
The New England Journal of Medicine published an editorial in March 2008 title: Learning from Aprotinin - Mandatory 
Trials of Comparative Efficacy and Safety Needed. The authors concluded the problems that have surfaced regarding Trasylol are going to be repeated in other drugs unless the FDA institutes changes in the requirements of postmarketing studies and restrictions on drug distribution and use. The magnitude of Trasylol kidney failure side effects and the potentially fatal consequences that have affected tens of thousands of heart surgery patients are becoming more and more evident.
The FDA first approved Trasylol (aprotinin) in 1993 to help prevent excessive blood loss during bypass surgery. It is estimated that by 2006, around 200,000 heart surgery patients had been prescribed aprotinin. Dr. Dennis Mangano and a group of researchers raised a red flag in 2006 and 2007 regarding the safety of Trasylol. Dr. Mangano published an observational study that showed Trasylol increased the risks of kidney failure, heart attack, stroke and death. The New England Journal of Medicine, in their editorial, asked the important question “What can we learn from the saga of aprotinin, a drug that apparently confers less overall benefit than cheaper alternatives yet has remained on the market for more than 14 years and become the recommended hemostatic agent for high-risk cardiac surgeries?”
According to the editorial, a crucial piece of the drug approval and monitoring process that is missing is the requirement for more information on infrequent but serious complications and performance relative to alternative drugs. In their opinion, the major lesson to be learned from the current Trasylol problems is that there needs to be head-to-head comparative trials when a new drug has alternatives. This needs to be done before a drug such as Trasylol is routinely administered for a large number of patients. Furthermore, they state that we cannot rely on the drug manufacturers to perform these studies on a voluntary basis because it is not in their commercial or financial interest to do so.
If you or a loved on has suffered from Trasylol kidney failure side effects or has died following heart surgery where Trasylol was used please contact our Trasylol attorneys for a free consultation or help finding out if Trasylol was used during surgery.
We are a Law Firm that is dedicated to helping people who have been affected by Trasylol side effects.
Personal Injury Law Firm
- Trasylol Lawsuit News | Trasylol Recall
- Trasylol Causing Kidney Failure After Heart Surgery | Trasylol Medical Records
- Trasylol Heart Surgery Kidney Failure Lawsuit
- Heart Surgery and Kidney Failure | Trasylol Class Action Suit
- Trasylol Kidney Failure Following Heart Surgery
- Trasylol Lawsuits and Patient Safety
- Trasylol Information News Video | Trasylol Class Action Lawsuit For Heart Surgery | Kidney Failure Stroke
Patients and families nationwide have looked at filing a Trasylol lawsuit based on the often fatal side effects of the drug Trasylol. Currently no Trasylol class action suits have been filed by Fields Law Firm and claims are being made individually.
The lawsuits claim that Bayer, the drug’s manufacturer, was negligent in several ways including:
• marketing [...]
The Trasylol heart surgery drug has increasingly been linked to serious side effects including kidney failure and stroke following bypass surgery. Many patients and families have questioned whether Bayer’s heart medication, also referred to as “Aprotinin“, was used during their procedure. The problem is that without looking at the medical records from the day of [...]
Bayer’s widely used Trasylol heart surgery drug was subject to a recall in 2007 following a study that raised safety concerns. Prior to the recall, Trasylol (also referred to as Aprotinin) was used to help prevent excessive bleeding during open heart surgery. The study reported that Bayer’s heart surgery medication increased the risk of dying [...]
Following a Trasylol recall in 2007, Bayer’s heart surgery drug continued to be used during heart surgery even though cheaper and safer alternative drugs were available. Unfortunately, Trasylol was used until as recently as May 2008.In 1993, Trasylol (also referred to as “aprotinin”) received FDA approval for use in certain types of heart surgeries. Until [...]
Bayer’s problems are growing as they face thousands of potential Trasylol lawsuits following increasing reports of their heart surgery drug’s side effects. Trasylol has recently been linked to a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved [...]
